India’s fight against COVID-19 is to be ferocious as Zydus Cadila’s vaccine ZyCoV-D gets approval from Drug Control General of India (DCGI). ZyCoV-D COVID vaccine from Cadila healthcare is now authorized for Children above age 12. ZyCoV-D COVID is DNA based vaccine. It is a three-shot vaccine which are to be given at 0, 28, 56 days’ time interval.
Emergency Use Authorization (EUA)
Zydus Cadila has been granted emergency use authorization by Drug Controller General of India (DCGI). ZyCoV-D COVID-19 vaccine is the first native originated and DNA based vaccine. It is to be provided for Children above age 12 as well as adults.
Three Shots and the Plug-and-Play Technology
ZyCoV-D COVID-19 vaccine is a three-shot vaccine. The first shot is to be given at 0, second shot at 28th and final third shot at 56th day. The Vaccine shot when given produces a projection of spike protein of virus SARS-CoV-2. It initiates an immune reaction which respond in playing a vital role and protects from the disease also works in viral clearing. It is a vaccine which does not require a needle for injecting it. It is an intradermal vaccine applied by using ‘Pharma Jet’ which make sure that the vaccination is painless. It is the first vaccine that India’s healthcare system accepts for children above 12. As DCGI authorized Zydus vaccine for emergency use it will be collaborating with other vaccines.
Prime Minister on Approval of ZyCoV-D COVID-19 Vaccine
Prime Minister Narendra Modi writes on his twitter handle on Friday praising Indian scientists over the EUA approval of Zydus Cadila’s ZyCoV-D the Made in India vaccine. PM Modi writes “@zydusUniverse is a testimony to the innovative zeal of India’s scientists. a momentous feat indeed”.
Narendra Modi on Twitter:
India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed. https://t.co/kD3t7c3Waz
— Narendra Modi (@narendramodi) August 20, 2021
Mission COVID Suraksha
The ZyCoV-D vaccine has been formulated under the ‘Mission COVID Suraksha’ in partnership with the Department of Biotechnology projected by BIRAC. The research has been supported by National Biopharma for preclinical studies.
The Chairman of Zydus Cadila Pankaj Patel said “We put out a safe, well tolerated and efficacious vaccine to fight COVID-19 with ZyCoV-D. To create the world’s first DNA vaccine at such a critical moment and in spite all the question, is a tribute to the Indian research scientists and their spirit of innovation“.
About BIRAC
Biotechnology Industry Research Assistance Council (BIRAC)has been set up by Department of Biotechnology (DBT). It is a non-for-profit Public Sector Enterprise
